Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET
Company Participants
Alexander Lobo - Stern Investor Relations
Milton Werner - CEO
Garth Lees-Rolfe - CFO
Conference Call Participants
Ed White - H.C. Wainwright
Operator
Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mr. Alexander Lobo, Stern Investor Relations. Thank you, Mr. Lobo. You may begin.
Alexander Lobo
Good morning and welcome to Inhibikase Therapeutics first quarter 2024 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer and Garth Lees-Rolfe, Chief Financial Officer. On May 15th, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2024. We encourage everyone to read yesterday's press release as well as Inhibikase quarterly report on form 10-Q, which is being filed with the SEC.
The company's press release and form 10-Q are also available on the Inhibikase website at inhibikase.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference.
Please note that certain information discussed on today's call is covered under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time sensitive information that is accurate only as of the date of this live broadcast May 16, 2024. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.
With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.
Milton Werner
Thank you, Alex. And thank you, everyone, for joining us today for to review our first quarter 2024 financial results and recent clinical and business updates. 2024 is shipping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points and we are proud of the achievements already accomplished by our team in the first quarter.